Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis
Sporadic lymphangioleiomyomatosis (S-LAM) is a rare lung disease characterized by the proliferation of smooth muscle-like LAM cells and progressive cystic destruction. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has a proven efficacy in patients with LAM. However, the therapeutic me...
Main Authors: | Yen-Lin Huang, Po-Ru Chen, Ying-Ju Lai, Hsao-Hsun Hsu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/8564 |
Similar Items
-
Lymphangioleiomyomatosis associated with prolactinoma: A case report and literature review
by: Yosuke Murakami, et al.
Published: (2021-01-01) -
Effects of sirolimus on Lung function in patients with Lymphangioleiomyomatosis
by: Fatemeh Aghaeimeybodi, et al.
Published: (2019-01-01) -
Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report
by: Ajay Kumar Verma, et al.
Published: (2018-01-01) -
Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study
by: Chongsheng Cheng, et al.
Published: (2022-07-01) -
Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series
by: Li Zhou, et al.
Published: (2018-09-01)